Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-12-12
2010-10-12
Russel, Jeffrey E (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S017400, C530S328000, C530S330000
Reexamination Certificate
active
07811995
ABSTRACT:
This invention generally relates to peptides useful for medical diagnosis and treatment of pathogenic disorders. More specifically, the invention relates to immunostimulatory peptides which can stimulate the production of therapeutically beneficial cytokines and, in combination with antibodies against human pathogens such as the immunodeficiency virus (HIV), inhibit replication of such pathogens. The peptides interact synergistically with pathogen-directed antibodies without producing or sustaining serious side-effects such as inflammation, and provide the potential for treatment modalities that are non-specific with respect to pathogen and cell type. Therefore, the peptides of the present invention have wide applicability with respect to medical treatment of pathogen-mediated infections, and the potential to enhance well-being.
REFERENCES:
patent: 5641747 (1997-06-01), Popoff et al.
patent: 5753481 (1998-05-01), Niwa et al.
patent: 6193981 (2001-02-01), Goldstein
patent: 6498020 (2002-12-01), Walker et al.
patent: 6551795 (2003-04-01), Rubenfield et al.
patent: 2004/0123343 (2004-06-01), La Rosa et al.
patent: 2004/0248192 (2004-12-01), Marchalonis et al.
patent: 2005/0063937 (2005-03-01), Li et al.
patent: 2006/0078535 (2006-04-01), Livant
patent: 2006/0148093 (2006-07-01), Gygi et al.
patent: 2006/0189538 (2006-08-01), Secombes et al.
patent: 2006/0269519 (2006-11-01), Chen et al.
patent: 2007/0003542 (2007-01-01), Zimmerman et al.
patent: 2008/0102076 (2008-05-01), Eggink et al.
patent: 2009/0041793 (2009-02-01), Eggink et al.
patent: 2290722 (2001-06-01), None
patent: 96/40903 (1996-12-01), None
patent: 00/31130 (2000-06-01), None
patent: 02/058589 (2002-08-01), None
patent: 03/091275 (2003-11-01), None
patent: 2004/011650 (2004-05-01), None
patent: 2005/087793 (2005-09-01), None
patent: 2006/063028 (2006-06-01), None
PCT/US2007/087425 International Search Report dated Aug. 5, 2008.
Sarig, et al.; “Telomeric and Tetraplex DNA Binding Properties of qTBP42: A Homoloque of the CArG Box Binding Protein CBF-A”; Biochemical and Biophysical Research Communications 1997, vol. 237, No. 3, pp. 617-623.
J. Cohen, “Hope on New AIDS Drugs, but Breast-Feeding Strategy Backfires,” Science (2007), vol. 315, pp. 1357.
J. Stover et al., “The Global Impact of Scaling up HIV/AIDS Prevention Programs in Low- and Middle-Income Countries,” Science (2006) vol. 311, pp. 1474-1476.
G. Fätkenheuer et al., “Efficacy of Short-Term Monotherapy with Maraviroc, a New CRC5 Antagonist, in Patients Infected with HIV 1,” Nature Med (2005), vol. 11, pp. 1170-1172.
Glaxosmithkline, (2005a) Study of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 in R5-Tropic Treatment-Experienced HIV Infected Subjects, ClinicalTrials.gov (Sep. 13, 2005) Identifier: NCT00197145S, (Terminated in 2005).
Glaxosmithkline, (2005b) “GlaxoSmithKline Halts Trials of Experimental CCR5 Inhibitor Aplaviroc in Treatment-naïve HIV Patients Due to Concerns about Liver Toxicity,” Statement to HIV Patient Community: Information from GlaxoSmithKline on Changes to Studies of Investigational CCR5 Entry Inhibitor Aplaviroc (GW873140) (Sep. 15, 2005), pp. 1-2.
P.W. Latham, “Therapeutic Peptides Revisited,” Nature Biotech (1999), vol. 17, pp. 755-757.
Supplementary European Search Report for European application No. 07871699.0 dated May 17, 2010 (8 sheets).
International Search Report for WO/2005/087793 dated Apr. 5, 2006 (6 sheets).
Written Opinion of the International Searching Authority for WO/2005/087793 dated Apr. 5, 2006 (7 sheets).
International Search Report for WO/2006/063028 dated Nov. 16, 2006 (6 sheets).
Written Opinion of the International Searching Authority for WO/2006/063028 dated Nov. 16, 2006 (9 sheets).
Written Opinion of the International Searching Authority for WO/2008/076815 dated Jul. 29, 2008 (6 sheets).
Written Opinion of the International Searching Authority for WO/2008/076824 dated Aug. 5, 2008 (6 sheets).
Ciesielski et al., “Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model”, Cancer Immunol Immunother, 54:107-119 (2005).
Eggink et al., “A biologically active peptide mimetic of N-acetylgalactosamine/galactose”, BMC Research Notes, 2:23 (2009).
Nicolaus, “Symbiotic Approach to Drug Design”, Decision Making in Drug Research, pp. 173-186 (Jan. 1, 1983).
Olszewska et al., “Protection against Measles Virus-Induced Encephalitis by Anti-mimotope Antibodies: The Role of Antibody Affinity”, Virology, 272(1):98-105 (Jun. 20, 2000).
Chargelegue et al., “A Peptide Mimic of a Protective Epitope of Respiratory Syncytial Virus Selected from a Combinatorial Library Induces Virus-Neutralizing Antibodies and Reduces Viral Load In Vivo”, Journal of Virology, 72(3):2040-2046 (Mar. 1998).
Chersi et al., “Specificities of rabbit antisera to multiple antigen (MAP) peptides”, Journal of Biosciences, 50(9-10):735-738 (Sep. 1, 1995) ABSTRACT ONLY.
Manki et al., “Vaccination with Multiple Antigen Peptide as Rejection Antigen Peptide in Murine Leukemia”, Cancer Research, 58:1960-1964 (May 1, 1998).
Nicolaus, “Symbiotic Approach to Drug Design”, Decision Making in Drug Research, pp. 173-186 (Jan. 1, 1983).
European Search Report for European patent application No. 07869233.2 dated May 11, 2010.
Eggink Laura L.
Hoober Kenneth J.
Fennemore Craig P.C.
Russel Jeffrey E
Susavion Biosciences, Inc.
LandOfFree
Therapeutic and diagnostic peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic and diagnostic peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic and diagnostic peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4169492